MedTrace Logo

Estimating the Impact of Obesity Medications on Clinical and Economic Outcomes

NCT07640139 · Status: ENROLLING_BY_INVITATION · Type: OBSERVATIONAL · Enrollment: 125000

Last updated 2026-06-10

No results posted yet for this study

Summary

The goal of this observational study is to identify the impact of incretin-based obesity medications (e.g., GLP-1 and GLP-1/GIP) on health and economic outcomes among adults who get their health insurance through their employers. The main questions it aims to answer are:

1. Is obesity medication usage is associated with reduced body mass index (BMI) and weight?
2. Is obesity medication usage is associated with reduced utilization of emergency department and inpatient care or obesity-related conditions over time?
3. Is obesity medication usage is associated with increased utilization of outpatient care over time?
4. Is obesity medication usage is associated with slower growth in direct medical costs over time?
5. Is obesity medication usage is associated with improvements in health measures?
6. Is obesity medication usage associated with reduced workplace costs?

Researchers will compare individuals who have prescriptions for obesity medications to those without to see if differences in health and costs of care exist.

The study uses existing medical and pharmacy claims data.

Conditions

Interventions

DRUG

Incretin-based therapies (GLP-1 and GLP-1/GIP)

Documented receipt of any GLP-1 and GLP-1/GIP obesity medication during an observation period.

Sponsors & Collaborators

Principal Investigators

  • Joshua R Vest, PhD, MPH · Indiana University

Eligibility

Min Age
18 Years
Max Age
64 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2026-01-01
Primary Completion
2029-12-31
Completion
2029-12-31
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07640139 on ClinicalTrials.gov